Home
AtaiBeckley

AtaiBeckley Market Share Analysis for July 2026

Explore the therapeutic areas where AtaiBeckley focuses its mental health innovation to address unmet patient needs.

Industry: N/A

Domainataibeckley.com

Year Founded--

Employees51 - 200

Annual Revenue--

AtaiBeckley

AtaiBeckley (including company regionals)

ataibeckley.com

See more website traffic and engagement information

Total visits to AtaiBeckley's top domains

Understand AtaiBeckley market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

ataibeckley.com32K

See more with Sales Intelligence

Avg. visit duration in AtaiBeckley's top domains

Analyze AtaiBeckley engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

ataibeckley.com00:01:54

See more with Sales Intelligence

Avg. pageviews on AtaiBeckley's top domains

See how AtaiBeckley keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

ataibeckley.com2.79

See more with Sales Intelligence

AtaiBeckley top competitors by domain

Top similar sites in July 2026, ranked by their affinity

clinicaltrialsarena.comCompany NameClinical Trials ArenaEmployees501 - 1000HQUnited States, New York, New YorkAnnual revenue$5M - $10MTotal visits158.5KHealth > Biotechnology and Pharmaceuticals

Top technologies used by AtaiBeckley

These are the website technologies, by industry, used by AtaiBeckley top domains

Conversion & Analytics (2)

Google Analytics

Email Services (2)

Microsoft Exchange Online

Mobile (2)

Meta Viewport

Advertising (1)

LinkedIn Advertiser

More Technologies

4

See all

News & Signals from AtaiBeckley

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsBeckley Psytech Limited is developing EMP-01 on Jul 20th '26.Furthermore, AtaiBeckley is working on EMP-01, an MDMA-based therapy for social anxiety disorder, as well as a research platform for non-hallucinogenic compounds for treating mental illnesses.

NewsBeckley Psytech Limited went public on Jul 18th '21.AtaiBeckley IPO'd in 2021 and has fallen 64% since going public.

NewsBeckley Psytech Limited is developing BPL-003 on Jul 16th '26.New York-based AtaiBeckley focuses on psychedelic-based treatments for mental health conditions and is developing BPL-003, an intranasal formulation of 5-MeO-DMT for treatment-resistant depression.